Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
the S&P 500 from 1990 to March 2026 shows both metrics declining in tandem over decades, with the sector's relative forward PE now sitting at Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up Quick Insights The sector's relative forward P/E declined from about 1.4x in the late 1990s to approximately 0.8x the S&P 500, reflecting diminished investor willingness to pay a premium as R&D intensity has decreased. High-growth biotech and emerging diagnostics stocks have elevated forward P/E ratios due to strong pipeline expectations rather than current earnings. The top five by forward P/E are Capricor Therapeutics, Legend Biotech Corporation, Amicus Therapeutics, Caris Life Sciences, and Corcept Therapeutics. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? [Yahoo! Finance]Yahoo! Finance
- Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics (CAPR) had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
- Capricor Therapeutics (CAPR) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $58.00 price target on the stock, up from $45.00.MarketBeat
- Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 3/12/26 - Miss
CAPR
Analyst Actions
- 3/10/26 - HC Wainwright
CAPR
Sec Filings
- 4/10/26 - Form ARS
- 4/10/26 - Form DEF
- 4/3/26 - Form 4
- CAPR's page on the SEC website